Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics (vol 15, pg 1947, 2014)

被引：0
|
作者：
Tay-Sontheimer, J.
Shireman, L. M.
Beyer, R. P.
机构：
来源：
PHARMACOGENOMICS | 2015年 / 16卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：913 / 913
页数：1
相关论文
共 50 条
  • [31] CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. (vol 11, pg 43, 2010)
    Gaedigk, Andrea
    Fuhr, Uwe
    Johnson, Charlene
    Berard, Anick
    Bradford, L. DiAnne
    Leeder, J. Steven
    PHARMACOGENOMICS, 2010, 11 (02) : 275 - 275
  • [32] Dextromethorphan to dextrorphan urinary metabolic ratio not sensitive enough to assess modest changes in CYP2D6 activity.
    Gorski, JC
    Li, L
    Hamman, MA
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P82 - P82
  • [33] Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population (vol 46, pg 18, 2000)
    Garcia-Barceló, M
    Chow, LY
    Chiu, HFK
    Wing, YK
    Lee, DTS
    Lam, KL
    Waye, MMY
    CLINICAL CHEMISTRY, 2000, 46 (11) : 1873 - 1873
  • [34] Activity and Kinetic Characterization of Four Human CYP2D6 Polymorphisms using the Substrates Bufuralol and Dextromethorphan
    Glass, Sarah
    Furge, Laura Lowe
    FASEB JOURNAL, 2016, 30
  • [35] Rapid detection of the intermediate metabolizer associated CYP2D6 polymorphisms*9 and*17 with real time PCR
    Steimer, W
    Müller, T
    Popp, J
    Heres, S
    Kissling, W
    Leucht, S
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 242 - 243
  • [36] ENDOBIOTICS FOR PHENOTYPING OF HUMAN CYTOCHROME P450 ENZYMES: USE OF METABOLOMICS FOR THE IDENTIFICATION OF NEW CYP2D6 ENDOGENOUS BIOMARKERS ON HEALTHY VOLUNTEERS
    Desmeules, Jules
    Magliocco, Gaelle
    Bararpour, Nasim
    Storelli, Flavia
    Daali, Youssef
    Thomas, Aurelien
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S28 - S28
  • [37] Induction of CYP2D6 Expression during Pregnancy Is Associated with an Increased Activity of Hepatocyte Nuclear Factor 4α
    Pan, Xian
    Koh, Kwihye
    Yu, Ai-Ming
    Jeong, Hyunyoung
    FASEB JOURNAL, 2013, 27
  • [38] DETECTION OF THE POOR METABOLIZER-ASSOCIATED CYP2D6(D) GENE DELETION ALLELE BY LONG-PCR TECHNOLOGY
    STEEN, VM
    ANDREASSEN, OA
    DALY, AK
    TEFRE, T
    BORRESEN, AL
    IDLE, JR
    GULBRANDSEN, AK
    PHARMACOGENETICS, 1995, 5 (04): : 215 - 223
  • [39] The 2988G>A polymorphism affects splicing of a CYP2D6 minigene (vol 80, pg 555, 2006)
    Rau, T.
    Diepenbruck, S.
    Diepenbruck, I
    Eschenhagen, T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) : 681 - 681
  • [40] Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort (vol 16, pg 566, 2016)
    Dodgen, T. M.
    Labuschagne, C. De J.
    van Schalkwyk, A.
    Steffens, F. E.
    Gaedigk, A.
    Cromarty, A. D.
    Alessandrini, M.
    Pepper, M. S.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (04): : 393 - 393
12345